Investment Rating - The report maintains a "Buy" investment rating for the company [9] Core Views - The company shows an upward trend in single-store performance and is advancing mergers and acquisitions to release production capacity [5][6] - The company reported a total revenue of 835 million yuan for H1 2025, representing a 9% year-on-year increase, and a net profit of 132 million yuan, up 18% year-on-year [4] - The gross margin improved by 2 percentage points to 28.23% in Q2 2025, driven by cost optimization and scale effects [5] - The company has successfully integrated the supply chain for the "Manxiangren" brand and is deepening market penetration in East China [6] Summary by Sections Financial Performance - For Q2 2025, total revenue reached 465 million yuan, a 14% increase year-on-year, with net profit rising by 31% to 94 million yuan [4][5] - The company’s EPS forecasts for 2025-2027 have been adjusted to 1.21, 1.32, and 1.42 yuan respectively, with corresponding PE ratios of 18, 17, and 16 times [9] Business Development - The company’s food revenue in Q2 2025 was 421 million yuan, with significant growth in customized filling products [6] - The franchise sales revenue reached 348 million yuan in Q2 2025, marking a 10% increase year-on-year, with a total of 5,685 franchise stores by the end of Q2 2025 [6] Market Strategy - The company is enhancing cooperation with major clients, achieving a 26% increase in group meal revenue to 106 million yuan in Q2 2025 [7] - Retail sales through channels like Hema and Tmall saw substantial growth, with increases of approximately 187% and 20% respectively in H1 2025 [7]